AIP and metabolic syndrome: The possible biological mechanisms linking higher AIP to increased MetS risk may involve dyslipidemia, with dyslipidemia’s role in CVD highlighted by the critical diagnostic criteria of triglycerides and HDL-C in MetS and the demonstrated contribution of triglyceride-rich particles to the development and progression of atheromatous plaques (17–19).